• AXIS Clinicals successfully completes 25th US FDA audit (November 2018)
  • AXIS Clinicals successfully completes 4th MHRA audit (June 2018)
  • AXIS Clinicals successfully completes 2nd WHO audit (December 2017)
  • AXIS Clinicals successfully completes AEMPS Spain (December 2018)
  • AXIS Clinicals successfully completes INFARMED Portugal (June 2018)
  • AXIS Clinicals successfully completes NPRA Malaysia (June 2018)
  • AXIS Clinicals successfully completes GCC audit (February 2016)
  • AXIS Clinicals successfully completes MCC South Africa audit (March 2017)
  • BA-BE studies conducted at AXIS Clinicals are accepted by Chile – ISP

PK | PD and Patient Studies

At AXIS Clinicals, we offer best-in-class services to conduct Patient population PK studies and clinical endpoint studies on healthy volunteers and patient population to assist our clients with their drug development programs. We have an extensive volunteer database and also have tie up with major hospitals and investigators’ to conduct patient PK studies and Clinical end point studies. We have enormous experience of conducting studies in all the major therapeutic areas, including renal impaired patients, hypogonadal patient’s, Cancer patients and Dermatology.

 


 

Fact sheet

  • 2,600+ clinical studies completed since inception
  • 350+ bioanalytical methods developed
  • 50+ successful Regulatory audits
  • Global footprint of operations with sites in India, U.S & Mexico.
  • Two clinical facilities (Hyderabad & Ahmedabad) in India
  • 100+ National and International Pharma/Biotech Sponsor companies working with AXIS
  • US FDA : 500+ approvals, EMEA : 100+ approvals, Canada : 50+ approvals, Australia : 50+ approvals
  • 500+ experienced employees working globally
  • Huge database of patient population in various therapeutic areas viz. Cardiology, Opthalmology, Schizophrenia, Diabetology, Oncology. Orthopedics etc..

Copyright Axis Clinicals - All Rights Reserved